4.7 Article

Genetic Factors of Renin-Angiotensin System Associated with Major Bleeding for Patients Treated with Direct Oral Anticoagulants

Journal

PHARMACEUTICS
Volume 14, Issue 2, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14020231

Keywords

direct oral anticoagulants; bleeding; renin-angiotensin system; polymorphisms; pharmacogenomics

Funding

  1. National Research Foundation of Korea (NRF) - Korea government (MSIT) [NRF-2020R1A2C1008120]

Ask authors/readers for more resources

The purpose of this study was to identify genetic factors related to the renin-angiotensin system (RAS) and its association with bleeding, and to develop a risk scoring system for bleeding in patients receiving direct oral anticoagulants (DOACs). The study found that older age and moderate to severe renal impairment were independent risk factors for bleeding, and certain RAS-related gene polymorphisms were also associated with increased bleeding risk. According to the risk scoring system, the risk of bleeding increased exponentially with a higher score.
The purpose of this study was to identify the renin-angiotensin system (RAS)-related genetic factors associated with bleeding and develop the bleeding risk scoring system in patients receiving direct oral anticoagulants (DOACs). This study was a retrospective analysis of prospectively collected samples from June 2018 to May 2020. To investigate the associations between RAS-related genetic factors and major bleeding, we selected 16 single nucleotide polymorphisms (SNPs) from five genes (namely, AGT, REN, ACE, AGTR1, and AGTR2). Multivariable logistic regression analysis was employed to investigate the independent risk factors for bleeding and to develop a risk scoring system. A total of 172 patients were included in the analysis, including 33 major bleeding cases. Both old age (>= 65 years) and moderate to severe renal impairment (CrCl < 50 mL/min) increased the risk of bleeding in the multivariable analysis. Among RAS-related polymorphisms, patients carrying TT genotype of rs5050 and A allele of rs4353 experienced a 3.6-fold (95% CI: 1.4-9.3) and 3.1-fold (95% CI: 1.1-9.3) increase in bleeding, respectively. The bleeding risk increased exponentially with a higher score; the risks were 0%, 2.8%, 16.9%, 32.7%, and 75% in patients with 0, 1, 2, 3, and 4 points, respectively. Although this study is limited to a retrospective study design, this is the first study to suggest RAS-related genetic markers and risk scoring systems, including both clinical and genetic factors, for major bleeding in patients receiving DOAC treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available